Virpax Pharmaceuticals (VRPX) AI Stock Analysis

• Market Cap: $13.29K
• Dividend Yield: N/A
• Average Volume (3M): 2.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.82
• Revenue Growth: N/A
• EPS Growth: 60.26%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 1,242,504
• 10 Day Avg. Volume: 1,988
• 30 Day Avg. Volume: 2,232
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.04
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: -112.78
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.17
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: $0.01 ▲(0.00% Upside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

The score is primarily constrained by very weak financial performance (no revenue, recurring losses, sharply higher 2024 losses and cash burn, and negative equity), which elevates financing and dilution risk. Technicals are also weak with the price below key moving averages, while valuation metrics provide little support due to non-meaningful P/E and no dividend yield data.

Positive Factors

Strategic Partnerships

Strategic partnerships and licensing agreements can provide a steady revenue stream and facilitate product development, enhancing long-term growth potential.

Innovative Drug Delivery Systems

The focus on innovative drug delivery systems positions Virpax to improve therapeutic outcomes, potentially capturing market share in pain management and neurological disorders.

Experienced Leadership

The addition of experienced leadership can strengthen strategic oversight and governance, aiding in navigating regulatory challenges and enhancing operational effectiveness.

Negative Factors

Financial Instability

Negative equity and financial instability pose significant risks to operational continuity, requiring urgent strategic pivots or capital injections to sustain business operations.

Zero Revenue

The absence of revenue generation highlights the pre-commercial stage of the company, increasing reliance on external financing and posing long-term sustainability challenges.

Leadership Changes

Frequent leadership changes can disrupt strategic direction and operational stability, potentially impacting investor confidence and the company's ability to execute its business plan.

Virpax Pharmaceuticals Business Overview & Revenue Model

Company Description

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

How the Company Makes Money

Virpax Pharmaceuticals makes money through the development and commercialization of its proprietary drug delivery systems and pharmaceutical products. The company's revenue model includes licensing agreements with other pharmaceutical companies and partnerships to co-develop and market their drug candidates. Additionally, Virpax seeks to generate income from milestone payments and royalties derived from successful commercialization of their therapies. Key revenue streams include developmental collaborations and strategic alliances with industry partners that enable the advancement of their product pipeline.

Virpax Pharmaceuticals Financial Statement Overview

Summary

Income statement shows no revenue with persistent and worsening losses, including a sharp deterioration in 2024. Cash flow remains deeply negative with a dramatic increase in 2024 cash burn, indicating heavy dependence on external funding. While debt is zero, the shift to negative equity in 2024 materially increases financial fragility and dilution risk.

Income Statement

The company reports no revenue across the annual periods provided, consistent with a pre-commercial biotech profile. Losses are persistent and sizable (net income negative every year), and profitability has not shown a durable improvement trend. The sharp deterioration in 2024 (annual) losses versus prior years is a key red flag and suggests materially higher spending or one-time charges, keeping overall earnings quality very weak.

Balance Sheet

Total debt is reported as zero in recent years, which reduces financial leverage risk. However, stockholders’ equity turns negative in 2024 (annual), a meaningful balance-sheet weakness that can limit financial flexibility and raise dilution risk. Assets have also declined substantially versus earlier years, pointing to a shrinking capital base despite the absence of debt.

Cash Flow

Operating cash flow and free cash flow are negative in every year shown, indicating ongoing cash burn with no internally generated funding. The cash outflow in 2024 (annual) is dramatically larger than prior years, implying a steep increase in burn and potentially a shorter runway. While free cash flow tracks net income closely, the overall profile remains highly dependent on external capital.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-12.08B	-14.69M	0.00	0.00	4.00K
Net Income	-12.07B	-15.19M	-21.46M	-12.15M	-4.49M
Balance Sheet
Total Assets	1.56B	9.63M	19.67M	39.57M	465.41K
Cash, Cash Equivalents and Short-Term Investments	1.51B	9.14M	19.00M	36.84M	54.80K
Total Debt	0.00	0.00	0.00	0.00	1.57M
Total Liabilities	2.47B	7.69M	3.09M	2.09M	4.68M
Stockholders Equity	-913.76M	1.93M	16.58M	37.48M	-4.22M
Cash Flow
Free Cash Flow	-16.71B	-9.85M	-17.85M	-14.54M	-1.38M
Operating Cash Flow	-16.71B	-9.85M	-17.85M	-14.54M	-1.38M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	9.08B	0.00	0.00	51.33M	1.40M

Virpax Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VRPX, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.10, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.33 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VRPX.

Virpax Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCNI	49 Neutral	$732.72K	-0.07	―	―	178.82%	-4121.10%
VRPX	40 Underperform	$13.29K	―	―	―	―	60.26%